CR

X-ray Detectors Market Worth $4.3 Billion by 2029 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®

Retrieved on: 
Tuesday, August 16, 2022 - 2:00pm
Death, First Nations in Ontario, Analogic Corporation, Mammography, Ageing, United Nations, Security, Fracture, X-ray, Pneumonia, Application, Diagnosis, Population, Technology, Growth, Fujifilm, Geography, CT, TFT, FOV, Prevalence, Person, History, Tuberculosis, CCD, Government, Income, CSI, Patient, Degenerative disease, COVID-19, Conditional sentence, Urbanization, CAGR, Flat, Canon Inc., Chronic condition, Impact, Weapon, CR, Life expectancy, Airport, Longevity, TB, FPD, Adoption, Medical imaging, Spine

The X-ray detectors are used in X-ray systems with wide applications in the medical, industrial, dental, veterinary, and security industries.

Key Points: 
  • The X-ray detectors are used in X-ray systems with wide applications in the medical, industrial, dental, veterinary, and security industries.
  • By 2050, one in four persons living in Europe and North America is estimated to be 65 years or over.
  • Quick Buy X-ray Detectors Market Research Report: https://www.meticulousresearch.com/Checkout/37090832
    Based on application, in 2022, the medical applications segment is expected to account for the largest share of the global X-ray detectors market.
  • Based on geography, in 2022, North America is expected to account for the largest share of the X-ray detectors market.

X-ray Detectors Market Worth $4.3 Billion by 2029 - Market Size, Share, Forecasts, & Trends Analysis Report with COVID-19 Impact by Meticulous Research®

Retrieved on: 
Tuesday, August 16, 2022 - 2:00pm
Death, First Nations in Ontario, Analogic Corporation, Mammography, Ageing, United Nations, Security, Fracture, X-ray, Pneumonia, Application, Diagnosis, Population, Technology, Growth, Fujifilm, Geography, CT, TFT, FOV, Prevalence, Person, History, Tuberculosis, CCD, Government, Income, CSI, Patient, Degenerative disease, COVID-19, Conditional sentence, Urbanization, CAGR, Flat, Canon Inc., Chronic condition, Impact, Weapon, CR, Life expectancy, Airport, Longevity, TB, FPD, Adoption, Medical imaging, Spine

The X-ray detectors are used in X-ray systems with wide applications in the medical, industrial, dental, veterinary, and security industries.

Key Points: 
  • The X-ray detectors are used in X-ray systems with wide applications in the medical, industrial, dental, veterinary, and security industries.
  • By 2050, one in four persons living in Europe and North America is estimated to be 65 years or over.
  • Quick Buy X-ray Detectors Market Research Report: https://www.meticulousresearch.com/Checkout/37090832
    Based on application, in 2022, the medical applications segment is expected to account for the largest share of the global X-ray detectors market.
  • Based on geography, in 2022, North America is expected to account for the largest share of the X-ray detectors market.

Crane Holdings, Co. Announces Transaction to Divest Legacy Asbestos Liabilities

Retrieved on: 
Monday, August 15, 2022 - 9:30pm
Defense, Chemicals, Plastics, Aerospace, Oil, Gas, Manufacturing, Energy, Contracts, Slate, Simpson Thacher & Bartlett, Hand, Forward-looking statement, NYSE, College of Arts and Sciences, Failure, Growth, SEC, Policy, Investment, Information, Sale, New, Crane Co., Fortress Investment Group, Company, Mission statement, Acquisition, Projection, Skadden, Water, Coronavirus, Payment, Asbestos, Insurance, China Academy of Aerospace Electronics Technology, Solution, Collection, CR, Aerospace, Risk management, Redco Pakistan Limited cricket team, Electronics

The transaction indemnifies Crane for all legacy asbestos liabilities.

Key Points: 
  • The transaction indemnifies Crane for all legacy asbestos liabilities.
  • Max Mitchell, Crane President and Chief Executive Officer stated: Todays announcement provides finality and certainty to investors regarding asbestos obligations, and it removes the distraction of asbestos related risks.
  • As a result of the transaction, Crane has removed all asbestos obligations and liabilities, related insurance assets, and associated deferred tax assets from the companys consolidated balance sheet.
  • Spruce Lakes capabilities extend to various types of legacy liabilities, but with a particular focus on asbestos related exposures.

IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, August 12, 2022 - 9:15pm
IPSC, U.S. Securities and Exchange Commission, CRS, ASCO, Risk, Haematopoietic system, Cell, Industry, Genentech, Senior, American Society of Clinical Oncology, DRI, Food and Drug Administration Amendments Act of 2007, Population, NEW, Leukemia, Annual general meeting, Private Securities Litigation Reform Act, Cytokine release syndrome, SEC, Business development, Clinical trial, GLOBE, R, NK, IND, Business, Patent, Society, Security (finance), Glioblastoma, AML, TLS, Patient, Gene, GBM, COVID-19, Company, CEO, Program, Novartis, Tumor lysis syndrome, Research, Hematopoietic stem cell transplantation, Regulatory affairs, Insurance, PFS, Nasdaq, CR, Deltex Medical Group, American Society of Gene and Cell Therapy, Progression-free survival, Food, Forward-looking statement, Bristol Myers Squibb, Vaccine, Pharmaceutical industry, Fine chemical

NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced financial results and operational highlights for the quarter ended June 30, 2022.

Key Points: 
  • NEW YORK, Aug. 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on discovering and developing innovative gamma-delta T cell therapies that utilize its DeltEx platform, today announced financial results and operational highlights for the quarter ended June 30, 2022.
  • In June 2022, IN8bio provided an update on the INB-200 Phase 1 clinical trial in newly diagnosed glioblastoma multiforme (GBM) patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • In June 2022, IN8bio held a successful pre-investigational new drug application (pre-IND) meeting with the Food and Drug Administration.
  • In July 2022, IN8bio provided an update from the ongoing Phase 1 clinical trial of INB-100 in leukemia patients undergoing haploidentical stem cell transplantation.

Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, August 10, 2022 - 9:05pm
FDA, Apoptosis, PLK1, CLL, Lymphoma, Histology, Biomarker, Risk, Hematology, CDK2, GLOBE, R, Breast, PTCL, Microdeletion syndrome, Clinical trial, Conference call, Cell cycle, Biliary tract, Research, Neoplasm, Annual report, ET, MCL1, CTCL, Income, Cyclin E, CDK9, Patient, COVID-19, CYCC, Company, Pancreatic cancer, PET, BCL2, Safety, Lymphatic system, MYC, NASDAQ, PK, KRAS, Â, All rights reserved, Treatment of lung cancer, News, Webcast, Simon, Ovarian cancer, CR, Conference, Toxic leukoencephalopathy, Food, Endometrial cancer, Vaccine, Fine chemical, Pharmaceutical industry, Medical imaging, Online gambling, Broadcasting, Cyclacel, Leukemia

- Oral fadraciclib demonstrated good tolerability with continuous dosing;

Key Points: 
  • - Oral fadraciclib demonstrated good tolerability with continuous dosing;
    - Conference call scheduled for August 10, 2022 at 4:30 pm ET -
    BERKELEY HEIGHTS, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced second quarter 2022 financial results and provided a business update.
  • In the second half of 2022 we are optimizing the dosing schedule to maximize target coverage and determine recommended Phase 2 dose (RP2D).
  • Tax credit receipts of $3.3 million in respect of the financial year ended December 31, 2021, were received in April 2022.
  • The Cyclacel logo and Cyclacel are trademarks of Cyclacel Pharmaceuticals, Inc.

Zai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates

Retrieved on: 
Tuesday, August 9, 2022 - 9:05pm
United, ASCO, PARP, NDA, CEO, GLOBE, American Society of Clinical Oncology, Face, Annual general meeting, Schizophrenia, NRDL, Society, Patient, SAN, NMPA, COO, NASDAQ, BLA, Webcast, ADP, Ovarian cancer, CR, Progression-free survival, Medicine, PRIME, III, Niraparib, Fine chemical, Pharmaceutical industry

ET

Key Points: 
  • ET
    SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced financial results for the second quarter of 2022, along with recent product highlights and corporate updates.
  • We executed well in the second quarter and delivered strong results, said Dr. Samantha Du, Founder, Chairperson and CEO, of Zai Lab.
  • I am thrilled to be joining Zai Lab at such a pivotal time in the companys history, said Josh Smiley, COO of Zai Lab.
  • In July 2022, Zai Lab treated the first patient in Greater China for the global Phase 3 KRYSTAL-12 study of adagrasib in patients with KRASG12C-mutated advanced NSCLC.

Caribou Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 9, 2022 - 9:00pm
EHA, CRISPR/Cpf1, Acute myeloid leukemia, U.S. Securities and Exchange Commission, Risk, Genome, Cell, Accounting, GLOBE, Technology, AbbVie, Private Securities Litigation Reform Act, Clinical trial, Poster, IND, Lymphatic system, Patent, Society, Security (finance), Research, Annual report, GlaxoSmithKline, Blood, AML, Gilead Sciences, Patient, European Hematology Association, DNA, Therapy, Gene, Biotechnology, RNA, Safety, G&A, MM, CRISPR, Phenotype, Rachel Haurwitz, Culture, Corporate Council on Africa, Insurance, Transplant, Nasdaq, CR, Reindeer, Efficiency, Cryptocurrency, Fine chemical, Pharmaceutical industry, Health insurance, Vaccine, Mobile phone, Sewing

-- Strong financial position of $366.1 million in cash, cash equivalents, and marketable securities as of June 30, 2022 --

Key Points: 
  • -- Additional cohort 1 data expected by YE 2022; enrolling patients in cohort 2 of ANTLER trial --
    -- Strong financial position of $366.1 million in cash, cash equivalents, and marketable securities as of June 30, 2022 --
    BERKELEY, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for the second quarter of 2022 and provided a business update.
  • CB-020: Caribou expects to announce target selection for CB-020, an iPSC-derived CAR-NK cell therapy for solid tumors, in Q4 2022.
  • Caribou Biosciences and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
  • Except as required by law, Caribou undertakes no obligation to update publicly any forward-looking statements for any reason.

Alcohol Detection Systems In Autos Could Prevent Thousands Of Deaths Each Year Becoming Big Business for Ride-Sharing

Retrieved on: 
Tuesday, August 9, 2022 - 2:15pm
Aurora, Q&A, U.S. Securities and Exchange Commission, Grab, City, CEO, Death, Security (finance), Research, Consumer Reports, Patient, EBITDA, Family, Securities Act of 1933, News, Green, NEVER, Securities Exchange Act of 1934, National Highway Traffic Safety Administration, Industry, LYFT, Technology, Private Securities Litigation Reform Act, NHTSA, Policy, Congress, Ridesharing, History, SOBR, NEWS, Form 10-K, Partnership, IIHS, PALM, Zomato, Insurance Institute for Highway Safety, Forward-looking statement, Growth, COVID, FNM, BAC, COVID-19, Acquisition, Parent, Solution, CR, Annual report, NYSE, Population, ANY, Yoy, Company, Crash, NOT, Transport, NASDAQ, Acadia, Second, Book, Ridesharing company, Uber, Safety, Lyft

That's nearly 30 percent of all motor vehicle fatalities, a percentage that has remained static every year over the last decade.

Key Points: 
  • That's nearly 30 percent of all motor vehicle fatalities, a percentage that has remained static every year over the last decade.
  • A sensor detects the amount of alcohol on the driver's breath, and if he or she is over the legal limit, the car won't start.
  • Unlike interlock devices, though, newer alcohol detection technology measures blood alcohol concentration (BAC) through normal breathing from the driver's seat.
  • This partnership represents SOBRsafe's entrance to ridesharing, and the industry's first opportunity for uniform, continuous alcohol safety monitoring.

Alcohol Detection Systems In Autos Could Prevent Thousands Of Deaths Each Year Becoming Big Business for Ride-Sharing

Retrieved on: 
Tuesday, August 9, 2022 - 2:15pm
Aurora, Q&A, U.S. Securities and Exchange Commission, Grab, City, CEO, Death, Security (finance), Research, Consumer Reports, Patient, EBITDA, Family, Securities Act of 1933, News, Green, NEVER, Securities Exchange Act of 1934, National Highway Traffic Safety Administration, Industry, LYFT, Technology, Private Securities Litigation Reform Act, NHTSA, Policy, Congress, Ridesharing, History, SOBR, NEWS, Form 10-K, Partnership, IIHS, PALM, Zomato, Insurance Institute for Highway Safety, Forward-looking statement, Growth, COVID, FNM, BAC, COVID-19, Acquisition, Parent, Solution, CR, Annual report, NYSE, Population, ANY, Yoy, Company, Crash, NOT, Transport, NASDAQ, Acadia, Second, Book, Ridesharing company, Uber, Safety, Lyft

That's nearly 30 percent of all motor vehicle fatalities, a percentage that has remained static every year over the last decade.

Key Points: 
  • That's nearly 30 percent of all motor vehicle fatalities, a percentage that has remained static every year over the last decade.
  • A sensor detects the amount of alcohol on the driver's breath, and if he or she is over the legal limit, the car won't start.
  • Unlike interlock devices, though, newer alcohol detection technology measures blood alcohol concentration (BAC) through normal breathing from the driver's seat.
  • This partnership represents SOBRsafe's entrance to ridesharing, and the industry's first opportunity for uniform, continuous alcohol safety monitoring.

PVH Corp. Releases 14th Annual Corporate Responsibility Report

Retrieved on: 
Monday, August 8, 2022 - 1:40pm
Jewelry, Other Retail, Luxury, Environmental Policy, Department Stores, Fashion, Recycling, Retail, Environment, Footwear, Sustainability, Carbon, Woman, Calvin Klein, Industry, NYSE, Corporate responsibility, Health, Corporation, PVH, Materiality, Clothing industry, Global Community Engagement and Resilience Fund, CR, Textile, Lists of companies, Management, Fashion, Renewable energy, Safety

PVH Corp. (NYSE:PVH), the growth platform for Calvin Klein and TOMMY HILFIGER, published today its 2021 Corporate Responsibility (CR) report.

Key Points: 
  • PVH Corp. (NYSE:PVH), the growth platform for Calvin Klein and TOMMY HILFIGER, published today its 2021 Corporate Responsibility (CR) report.
  • Forward Fashion, our global corporate responsibility strategy, continues to be our roadmap for making a positive impact.
  • We understand and recognize our responsibility to make a positive impact for both our stakeholders and our industry, said Rick Relinger, PVH Corp. Chief Sustainability Officer.
  • This years report chronicles notable progress against PVHs Forward Fashion commitments and also displays improvements on how and what the company reported.